Natixis Advisors Boosts Stake in Bio-Rad Laboratories

Investment firm increases holding in medical research company by 67.1% in Q3

Mar. 12, 2026 at 9:51am

Got story updates? Submit your updates here. ›

Natixis Advisors LLC, an investment management firm, grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 67.1% during the third quarter of 2025, according to a recent SEC filing. The firm now owns 65,069 shares of the medical research company's stock, worth approximately $18.2 million.

Why it matters

Bio-Rad Laboratories is a leading provider of life science research and clinical diagnostic products, operating in the highly competitive medical technology industry. Institutional investors like Natixis Advisors closely monitor and adjust their holdings in companies like Bio-Rad, which can signal broader market trends and investor sentiment.

The details

Natixis Advisors purchased an additional 26,119 shares of Bio-Rad Laboratories during the third quarter, increasing its total stake in the company to 65,069 shares. This represents approximately 0.24% of Bio-Rad's outstanding shares. The investment firm cited Bio-Rad's strong market position, innovative product pipeline, and growth potential as factors behind the increased investment.

  • Natixis Advisors grew its position in Bio-Rad Laboratories during the 3rd quarter of 2025.

The players

Natixis Advisors LLC

An investment management firm that grew its stake in Bio-Rad Laboratories by 67.1% in the third quarter of 2025.

Bio-Rad Laboratories, Inc.

A global provider of life science research and clinical diagnostic products, operating in the medical technology industry.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Natixis Advisors in Bio-Rad Laboratories reflects the firm's confidence in the company's long-term growth potential within the dynamic medical technology sector. This transaction highlights the ongoing interest and activity of institutional investors in the space.